Martinsried/Munich, 04 April 2016. Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immune-oncology company focussing on the development of T cell-based immunotherapies for the treatment of cancer, announces that it has today sold 50% of its' stake in the private biotech company Immunocore Ltd., UK, for approximately 4.9 million GBP (approx. € 6.1 million).
Medigene held 64,815 ordinary shares in Immunocore which were valued at 2.8 million GBP (approx. € 3.6 million) in 2014.
Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Lochhamer Str. 11 82152
Tel.: +49 - 89 - 20 00 33 - 33 01,